Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BYFrontiers in Medicine

A case of severe recurrent VKH-like uveitis following BRAF/MEK inhibitor therapy: a case report and review of the literature

  • Lena Juratli1
  • Devayu A. Parikh1
  • Christopher D. Conrady1
  • Christopher D. Conrady2
  1. 1Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah, Salt Lake City, UT, United States
  2. 2Department of Pathology, University of Utah, Salt Lake City, UT, United States
Read full textDOICite

Abstract

BRAF and MEK inhibitors are increasingly used as targeted anticancer therapies. However, they are associated with vision-threatening ocular toxicities. We present the case of a 68-year-old woman who developed severe, recurrent VKH-like uveitis that progressed despite corticosteroid therapy and a reduced-dose drug rechallenge. The constellation of findings, including bilateral panuveitis, exudative retinal detachments, diffuse choroidal thickening, subsequent sunset-glow fundus changes, retinal pigment epithelium clumping, a negative inflammatory and infectious workup, improvement following drug withdrawal, and recurrence after medication rechallenge, supported the diagnosis of VKH-like uveitis secondary to dabrafenib and trametinib. Although some patients may be successfully managed with corticosteroids and treatment modification, our case demonstrates that recurrent VKH-like inflammation can progress despite aggressive local and systemic immunosuppression and cancer treatment adjustments. Given the increasing number of reported cases and the high incidence and hazard ratios observed in recent studies, development of formal management guidelines should be considered.

Related

  1. Fire needle therapy for recurrent skin and soft tissue infections: a case report and literature review
    Wenqing Xu, Zuohang Zhou, Haixu Jin +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy
    D. Bukovec, M. Gjorgjievska, S. Kocevska +5
    medRxivPreprintAll rights reservedFull textOncologymedRxiv
  3. Case Report: Four-year durable remission, cerebral oligoprogression, and femoral head necrosis following severe recurrent immune checkpoint inhibitor-related pneumonitis in a patient with stage IV lung adenocarcinoma
    Yanjun Xue, Aizhen Xu, Xin Tong +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCEurope PMCPMC
  4. Acute Myocardial Infarction from Stent Thrombosis Following a Loss to Follow-up Triggered by Financial Barriers to PCSK9 Inhibitor Therapy
    Tetsuro Nagao, Riku Arai, Tokio Nishiwaki +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaJ-STAGE
  5. A Case of Recurrent COVID-19 Pneumonia Following Rituximab Therapy: Treatment Informed by a Serial Transbronchial Lung Cryobiopsy, BALF SARS-CoV-2 PCR, and the Clinical Course
    Jun Hayashi, Tatsuya Nagai, Kurumi Seki +11
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textInfectious diseaseJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{juratli2026case,
  title = {{A case of severe recurrent VKH-like uveitis following BRAF/MEK inhibitor therapy: a case report and review of the literature}},
  author = {Lena Juratli and Devayu A. Parikh and Christopher D. Conrady and Christopher D. Conrady},
  journal = {Frontiers in Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fmed.2026.2014176},
  url = {https://doi.org/10.3389/fmed.2026.2014176},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - A case of severe recurrent VKH-like uveitis following BRAF/MEK inhibitor therapy: a case report and review of the literature
AU  - Lena Juratli
AU  - Devayu A. Parikh
AU  - Christopher D. Conrady
AU  - Christopher D. Conrady
PY  - 2026
DA  - 2026/11/09
JO  - Frontiers in Medicine
DO  - 10.3389/fmed.2026.2014176
UR  - https://doi.org/10.3389/fmed.2026.2014176
AB  - BRAF and MEK inhibitors are increasingly used as targeted anticancer therapies. However, they are associated with vision-threatening ocular toxicities. We present the case of a 68-year-old woman who developed severe, recurrent VKH-like uveitis that progressed despite corticosteroid therapy and a reduced-dose drug rechallenge. The constellation of findings, including bilateral panuveitis, exudative retinal detachments, diffuse choroidal thickening, subsequent sunset-glow fundus changes, retinal pigment epithelium clumping, a negative inflammatory and infectious workup, improvement following drug withdrawal, and recurrence after medication rechallenge, supported the diagnosis of VKH-like uveitis secondary to dabrafenib and trametinib. Although some patients may be successfully managed with corticosteroids and treatment modification, our case demonstrates that recurrent VKH-like inflammation can progress despite aggressive local and systemic immunosuppression and cancer treatment adjustments. Given the increasing number of reported cases and the high incidence and hazard ratios observed in recent studies, development of formal management guidelines should be considered.
SN  - 2296-858X
ER  -